Literature DB >> 25440610

From monoclonal antibodies to chimeric antigen receptors for the treatment of human malignancies.

Ignazio Caruana1, Iulia Diaconu1, Gianpietro Dotti2.   

Abstract

Monoclonal antibodies (mAbs) and their directly derived cell-based application known as chimeric antigen receptors (CARs) ensue from the need to develop novel therapeutic strategies that retain high anti-tumor activity, but carry reduced toxicity compared to conventional chemo- and radiotherapies. In this concise review article, we will summarize the application of antibodies designed to target antigens expressed by tumor cells, and the transition from these antibodies to the generation of CARs.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25440610      PMCID： PMC4254449          DOI： 10.1053/j.seminoncol.2014.08.005

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


  49 in total

1.  Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.

Authors:  Cor H J Lamers; Stefan Sleijfer; Arnold G Vulto; Wim H J Kruit; Mike Kliffen; Reno Debets; Jan W Gratama; Gerrit Stoter; Egbert Oosterwijk
Journal:  J Clin Oncol       Date:  2006-05-01       Impact factor: 44.544

2.  Monoclonal antibodies in cancer therapy: 25 years of progress.

Authors:  Robert K Oldham; Robert O Dillman
Journal:  J Clin Oncol       Date:  2008-04-10       Impact factor: 44.544

3.  T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells.

Authors:  Juan Vera; Barbara Savoldo; Stephane Vigouroux; Ettore Biagi; Martin Pule; Claudia Rossig; Jessie Wu; Helen E Heslop; Cliona M Rooney; Malcolm K Brenner; Gianpietro Dotti
Journal:  Blood       Date:  2006-08-22       Impact factor: 22.113

Review 4.  Development trends for monoclonal antibody cancer therapeutics.

Authors:  Janice M Reichert; Viia E Valge-Archer
Journal:  Nat Rev Drug Discov       Date:  2007-05       Impact factor: 84.694

5.  Regression of experimental medulloblastoma following transfer of HER2-specific T cells.

Authors:  Nabil Ahmed; Maheshika Ratnayake; Barbara Savoldo; Laszlo Perlaky; Gianpietro Dotti; Winfried S Wels; Meenakshi B Bhattacharjee; Richard J Gilbertson; H David Shine; Heidi L Weiss; Cliona M Rooney; Helen E Heslop; Stephen Gottschalk
Journal:  Cancer Res       Date:  2007-06-15       Impact factor: 12.701

6.  Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.

Authors:  Ralf Bargou; Eugen Leo; Gerhard Zugmaier; Matthias Klinger; Mariele Goebeler; Stefan Knop; Richard Noppeney; Andreas Viardot; Georg Hess; Martin Schuler; Hermann Einsele; Christian Brandl; Andreas Wolf; Petra Kirchinger; Petra Klappers; Margit Schmidt; Gert Riethmüller; Carsten Reinhardt; Patrick A Baeuerle; Peter Kufer
Journal:  Science       Date:  2008-08-15       Impact factor: 47.728

Review 7.  Follicular NHL: from antibodies and vaccines to graft-versus-lymphoma effects.

Authors:  David G Maloney
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2007

8.  Expression of the heparan sulfate-degrading enzyme heparanase is induced in infiltrating CD4+ T cells in experimental autoimmune encephalomyelitis and regulated at the level of transcription by early growth response gene 1.

Authors:  Amanda M de Mestre; Maria A Staykova; June R Hornby; David O Willenborg; Mark D Hulett
Journal:  J Leukoc Biol       Date:  2007-07-26       Impact factor: 4.962

Review 9.  Head and neck cancer immunotherapy: clinical evaluation.

Authors:  Michael S Leibowitz; Jayakar V Nayak; Robert L Ferris
Journal:  Curr Oncol Rep       Date:  2008-03       Impact factor: 5.075

10.  Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.

Authors:  Conrad Russell Y Cruz; Kenneth P Micklethwaite; Barbara Savoldo; Carlos A Ramos; Sharon Lam; Stephanie Ku; Oumar Diouf; Enli Liu; A John Barrett; Sawa Ito; Elizabeth J Shpall; Robert A Krance; Rammurti T Kamble; George Carrum; Chitra M Hosing; Adrian P Gee; Zhuyong Mei; Bambi J Grilley; Helen E Heslop; Cliona M Rooney; Malcolm K Brenner; Catherine M Bollard; Gianpietro Dotti
Journal:  Blood       Date:  2013-09-12       Impact factor: 22.113
View more
  16 in total

1.  Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells.

Authors:  Martin Felices; Todd R Lenvik; Zachary B Davis; Jeffrey S Miller; Daniel A Vallera
Journal:  Methods Mol Biol       Date:  2016

Review 2.  Rapid Fire: Infectious Disease Emergencies in Patients with Cancer.

Authors:  Stephanie Charshafian; Stephen Y Liang
Journal:  Emerg Med Clin North Am       Date:  2018-06-11       Impact factor: 2.264

3.  Characterization of a Novel Third-Generation Anti-CD24-CAR against Ovarian Cancer.

Authors:  Rüdiger Klapdor; Shuo Wang; Michael Morgan; Thilo Dörk; Ulrich Hacker; Peter Hillemanns; Hildegard Büning; Axel Schambach
Journal:  Int J Mol Sci       Date:  2019-02-03       Impact factor: 5.923

Review 4.  Chimeric Antigen Receptor T Cell Therapy: A Novel Modality for Immune Modulation.

Authors:  Somy Yoon; Gwang Hyeon Eom
Journal:  Chonnam Med J       Date:  2020-01-22

Review 5.  Manipulating the Metabolism to Improve the Efficacy of CAR T-Cell Immunotherapy.

Authors:  Marsha Pellegrino; Francesca Del Bufalo; Biagio De Angelis; Concetta Quintarelli; Ignazio Caruana; Emmanuel de Billy
Journal:  Cells       Date:  2020-12-24       Impact factor: 6.600

Review 6.  Tumor Profiling at the Service of Cancer Therapy.

Authors:  Ceres Fernandez-Rozadilla; Ana Rita Simões; Matilde E Lleonart; Amancio Carnero; Ángel Carracedo
Journal:  Front Oncol       Date:  2021-01-11       Impact factor: 6.244

7.  Identification of neuroblastoma cell lines with uncommon TAZ+/mesenchymal stromal cell phenotype with strong suppressive activity on natural killer cells.

Authors:  Claudia Canzonetta; Andrea Pelosi; Sabina Di Matteo; Ignazio Caruana; Bruno Azzarone; Irene Veneziani; Nicola Tumino; Paola Vacca; Enrico Munari; Marco Pezzullo; Charles Theuer; Rita De Vito; Vito Pistoia; Luigi Tomao; Franco Locatelli; Lorenzo Moretta
Journal:  J Immunother Cancer       Date:  2021-01       Impact factor: 13.751

8.  GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.

Authors:  Franco Locatelli; Valentina Folgiero; Matteo Caforio; Cristina Sorino; Ignazio Caruana; Gerrit Weber; Antonio Camera; Loredana Cifaldi; Biagio De Angelis; Francesca Del Bufalo; Alessia Vitale; Bianca Maria Goffredo; Rita De Vito; Doriana Fruci; Concetta Quintarelli; Maurizio Fanciulli
Journal:  J Immunother Cancer       Date:  2021-03       Impact factor: 13.751

Review 9.  Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics.

Authors:  Karie Runcie; Daniel R Budman; Veena John; Nagashree Seetharamu
Journal:  Mol Med       Date:  2018-09-24       Impact factor: 6.354

10.  Universal Ready-to-Use Immunotherapeutic Approach for the Treatment of Cancer: Expanded and Activated Polyclonal γδ Memory T Cells.

Authors:  Vinicia A Polito; Rosaria Cristantielli; Gerrit Weber; Francesca Del Bufalo; Tamascia Belardinilli; Claudia M Arnone; Andrea Petretto; Laura Antonucci; Ezio Giorda; Nicola Tumino; Angela Pitisci; Biagio De Angelis; Concetta Quintarelli; Franco Locatelli; Ignazio Caruana
Journal:  Front Immunol       Date:  2019-11-22       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.